Psychemedics Q3 revenue down 3% to $6.5M, net loss of $0.1M; declares $0.07 dividend

PSYCHEMEDICS CORP

2022-Q3 EPS reported -$0.07 revenue$19,537,000

Revenue $6.5M vs $6.7M YoY (-3%); net loss $0.1M ($0.02/sh) vs net income $0.7M ($0.13/sh).
Nine-month revenue $19.5M (+5% YoY); net loss $0.4M ($0.07/sh) vs net income $1.0M ($0.17/sh).
Quarterly cash dividend of $0.07/sh declared, payable Dec 16, 2022 to holders of record Dec 2, 2022.
Prior-year quarter included $1.0M Employee Retention Credit; excluding ERC, gross margins were flat.
Cash $3.5M at Sep 30, 2022, up from $2.0M at Dec 31, 2021; equipment financing reduced to $0.7M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PSYCHEMEDICS CORP reported the third quarter ended September 30, 2022 results: revenue $6.5 million, net income $0.1 million, EPS ($0.02) per diluted share.

Period: the third quarter ended September 30, 2022
Revenue: $6.5 million
Net income: $0.1 million
EPS: ($0.02) per diluted share
Result: reported results

Exact text from the filing

The Company’s revenue for the quarter ended September 30, 2022, was $6.5 million versus $6.7 million for the quarter ended September 30, 2021, a decrease of 3%. Net loss for the quarter ended September 30, 2022, was $0.1 million or ($0.02) per diluted share, versus net income of $0.7 million or $0.13 per diluted share, for the comparable quarter last year.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PSYCHEMEDICS CORP reported the nine months ended September 30, 2022 results: revenue $19.5 million, net income $0.4 million, EPS ($0.07) per diluted share.

Period: the nine months ended September 30, 2022
Revenue: $19.5 million
Net income: $0.4 million
EPS: ($0.07) per diluted share
Result: reported results

Exact text from the filing

The Company’s revenue for the nine months ended September 30, 2022, was $19.5 million versus $18.5 million for the comparable period in 2021, an increase of 5%. Net loss for the nine months ended September 30, 2022, was $0.4 million or ($0.07) per diluted share, versus net income of $1.0 million or $0.17 per diluted share, for the comparable period last year.

View on SEC.gov

Browse all earnings releases →

PSYCHEMEDICS CORP filing history →

Source: SEC EDGAR

accession 0001171843-22-007301

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.